Abstract |
FKBP, a naturally occurring ubiquitous intracellular protein, has been proposed as a potential target for coronavirus replication. A non-immunosuppressive FKBP ligand, FK1706, was studied in vitro in a Vero cell model to assess potential activity alone and in combination with antivirals against SARS-CoV-2 replication. When combined with remdesivir, synergistic activity was seen (summary synergy score 24.7±9.56). FK1706 warrants in vivo testing as a potential new combination therapeutic for the treatment of COVID-19 infections.
|
Authors | William E Fitzsimmons, Tracy L Hartman, Michelle Mendenhall, Catherine Z Chen |
Journal | bioRxiv : the preprint server for biology
(bioRxiv)
(Feb 07 2022)
United States |
PMID | 35169800
(Publication Type: Preprint)
|